Agmatine ameliorates diabetes type 2-induced nephropathy in rats
- Author:
Fatemah O. Kamel
1
;
Ohoud Shagroud
1
;
Mai A.Alim A.Sattar Ahmad
1
;
Gamal S Abd Gamal El-Aziz
2
;
Abdulhadi S. Burzangi
1
;
Duaa Bakhshwin
1
;
Maha Jamal
1
;
Shahid Karim
1
Author Information
- Publication Type:Journal Article
- Keywords: Agmatine; Type 2 diabetes; Nephropathy; Oxidative stress; Nephroprotection
- From:Asian Pacific Journal of Tropical Biomedicine 2024;14(1):8-16
- CountryChina
- Language:English
- Abstract: Objective: To assess the nephroprotective potential of agmatine in a rat model of streptozotocin-induced diabetic nephropathy. Methods: A single dose of streptozotocin (40 mg/kg) coupled with a fructose diet induced diabetes in Wistar rats. Agmatine (40 and 80 mg/kg) was administered to rats for 12 weeks. The body weight and fasting blood glucose were measured weekly. Insulin level, urine output, total protein, albumin, blood urea nitrogen, creatinine, and cystatin-C were also determined at the end of the experiment. Furthermore, superoxide dismutase, glutathione, interleukin-1β, interleukin-6, and tumor necrosis factor-alpha were evaluated in kidney tissue. Histopathological study was also performed using hematoxylin and eosin staining. Results: Agmatine at both doses significantly increased final body weight, and lowered fasting blood glucose, urine output, insulin, total protein, albumin, blood urea nitrogen, creatinine, and cystatin-C levels compared with the diabetic group (P < 0.05). Inflammatory markers and antioxidant effect were significantly improved in agmatine-treated rats. Moreover, the histopathological changes in renal structure were ameliorated by agmatine treatment. Conclusions: Agmatine alleviates diabetic nephropathy by improving renal functions and reducing inflammation and oxidative stress. The molecular mechanisms of its nephroprotective actions need to be investigated in future study.
- Full text:20240102.pdf
